{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:15:55Z","timestamp":1790806555370,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","award":["KLET-201911"],"award-info":[{"award-number":["KLET-201911"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","award":["A2024664"],"award-info":[{"award-number":["A2024664"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.numecd.2025.104379","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T22:59:35Z","timestamp":1760655575000},"page":"104379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacomicrobiomics: Exploring the role of gut microbiota in type 2 diabetes and antidiabetic drug mechanisms"],"prefix":"10.1016","volume":"36","author":[{"given":"Dingsheng","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9539-5710","authenticated-orcid":false,"given":"Xiangyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2025.104379_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.numecd.2025.104379_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2337\/dc17-1827","article-title":"Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered Short- and long-term glycemic response to DPP-4 inhibitor therapy","volume":"41","author":"Dennis","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.numecd.2025.104379_bib3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s13238-018-0547-2","article-title":"Pharmacomicrobiomics: a novel route towards personalized medicine?","volume":"9","author":"Doestzada","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.numecd.2025.104379_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fcimb.2018.00424","article-title":"MDAD: a special resource for microbe-drug associations","volume":"8","author":"Sun","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"10.1016\/j.numecd.2025.104379_bib5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1089\/omi.2014.0018","article-title":"Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics","volume":"18","author":"ElRakaiby","year":"2014","journal-title":"OMICS"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/healthcare3010100","article-title":"The microbiome and sustainable healthcare","volume":"3","author":"Dietert","year":"2015","journal-title":"Healthcare (Basel)"},{"issue":"12","key":"10.1016\/j.numecd.2025.104379_bib7","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.mayocp.2017.10.004","article-title":"Microbiome at the frontier of personalized medicine","volume":"92","author":"Kashyap","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.numecd.2025.104379_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev-pharmtox-042017-031849","article-title":"Impacts of the human gut microbiome on therapeutics","volume":"58","author":"V\u00e1zquez-Baeza","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1757-4749-4-16","article-title":"Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes","volume":"4","author":"Saad","year":"2012","journal-title":"Gut Pathog"},{"key":"10.1016\/j.numecd.2025.104379_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.maturitas.2018.03.012","article-title":"Microbiota-drug interactions: impact on metabolism and efficacy of therapeutics","volume":"112","author":"Wilkinson","year":"2018","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40168-018-0483-7","article-title":"Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies","volume":"6","author":"Panebianco","year":"2018","journal-title":"Microbiome"},{"issue":"10","key":"10.1016\/j.numecd.2025.104379_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/17425255.2018.1530216","article-title":"Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions","volume":"14","author":"Aziz","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"10.1016\/j.numecd.2025.104379_bib13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/jama.300.7.777","article-title":"Microbiome project seeks to understand human body's microscopic residents","volume":"300","author":"Friedrich","year":"2008","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.numecd.2025.104379_bib14","first-page":"8","article-title":"Human microbiome as an approach to personalized medicine","volume":"23","author":"Ejtahed","year":"2017","journal-title":"Alternative Ther Health Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/pgs.10.157","article-title":"Pharmacometabonomics as an effector for personalized medicine","volume":"12","author":"Nicholson","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.numecd.2025.104379_bib16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/bib\/bbs002","article-title":"Data mining the human gut microbiota for therapeutic targets","volume":"13","author":"Collison","year":"2012","journal-title":"Briefings Bioinf"},{"issue":"4","key":"10.1016\/j.numecd.2025.104379_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/omi.2018.0041","volume":"22","author":"Aziz","year":"2018","journal-title":"The Dawn of Pharmacomicrobiomics Omics"},{"issue":"Pt 6","key":"10.1016\/j.numecd.2025.104379_bib18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/0004563213497929","article-title":"Pharmacometabonomics and personalized medicine","volume":"50","author":"Everett","year":"2013","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.numecd.2025.104379_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fgene.2015.00219","article-title":"From next-generation sequencing to systematic modeling of the gut microbiome","volume":"6","author":"Ji","year":"2015","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40168-017-0373-4","article-title":"The gut mycobiome of the Human Microbiome Project healthy cohort","volume":"5","author":"Nash","year":"2017","journal-title":"Microbiome"},{"issue":"11","key":"10.1016\/j.numecd.2025.104379_bib21","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/s41588-018-0224-7","article-title":"Individual variations in cardiovascular-disease-related protein levels are driven by genetics and gut microbiome","volume":"50","author":"Zhernakova","year":"2018","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.numecd.2025.104379_bib22","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1053\/j.gastro.2016.12.048","article-title":"Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction","volume":"152","author":"Bouter","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.numecd.2025.104379_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.tig.2023.02.006","article-title":"The gut microbiota links disease to human genome evolution","volume":"39","author":"Quan","year":"2023","journal-title":"Trends Genet"},{"issue":"12","key":"10.1016\/j.numecd.2025.104379_bib24","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41564-017-0072-8","article-title":"Enterotypes in the landscape of gut microbial community composition","volume":"3","author":"Costea","year":"2018","journal-title":"Nat Microbiol"},{"issue":"4","key":"10.1016\/j.numecd.2025.104379_bib26","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/advances\/nmaa181","article-title":"Diet and the microbiota-gut-brain axis: sowing the seeds of good mental health","volume":"12","author":"Berding","year":"2021","journal-title":"Adv Nutr"},{"issue":"22","key":"10.1016\/j.numecd.2025.104379_bib27","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1080\/10408398.2021.1898336","article-title":"High animal protein diet and gut microbiota in human health","volume":"62","author":"Cai","year":"2022","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"2","key":"10.1016\/j.numecd.2025.104379_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.chom.2019.06.013","article-title":"Meta-Analysis reveals reproducible gut microbiome alterations in response to a high-fat diet","volume":"26","author":"Bisanz","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2021.1882926","article-title":"Ethnic variability associating gut and oral microbiome with obesity in children","volume":"13","author":"Balakrishnan","year":"2021","journal-title":"Gut Microbes"},{"issue":"33","key":"10.1016\/j.numecd.2025.104379_bib30","doi-asserted-by":"crossref","first-page":"14691","DOI":"10.1073\/pnas.1005963107","article-title":"Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa","volume":"107","author":"De Filippo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.numecd.2025.104379_bib31","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/gutjnl-2012-303184","article-title":"Gut microbiota disturbance during antibiotic therapy: a multi-omic approach","volume":"62","author":"P\u00e9rez-Cobas","year":"2013","journal-title":"Gut"},{"issue":"7698","key":"10.1016\/j.numecd.2025.104379_bib32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nature25979","article-title":"Extensive impact of non-antibiotic drugs on human gut bacteria","volume":"555","author":"Maier","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.numecd.2025.104379_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41579-023-00963-6","article-title":"The oral microbiome: diversity, biogeography and human health","volume":"22","author":"Baker","year":"2024","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"10.1016\/j.numecd.2025.104379_bib34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.chom.2021.02.021","article-title":"Developmental trajectory of the healthy human gut microbiota during the first 5 years of life","volume":"29","author":"Roswall","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"9","key":"10.1016\/j.numecd.2025.104379_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41575-022-00605-x","article-title":"The gut microbiome as a modulator of healthy ageing","volume":"19","author":"Ghosh","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2025.104379_bib36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3389\/fphar.2016.00411","article-title":"Pharmacometabolomics informs viromics toward precision medicine","volume":"7","author":"Balasopoulou","year":"2016","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.numecd.2025.104379_bib37","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.apsb.2020.09.013","article-title":"The influence of the gut microbiota on the bioavailability of oral drugs","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"19","key":"10.1016\/j.numecd.2025.104379_bib38","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1161\/01.CIR.100.19.2025","article-title":"Evidence-based analysis of amiodarone efficacy and safety","volume":"100","author":"Connolly","year":"1999","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.numecd.2025.104379_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087150","article-title":"Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats","volume":"9","author":"Matuskova","year":"2014","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.numecd.2025.104379_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201800146","article-title":"Novel mechanism of Fatty acid sensing in enteroendocrine cells: specific structures in Oxo-Fatty acids produced by gut bacteria are responsible for CCK secretion in STC-1 cells via GPR40","volume":"62","author":"Hira","year":"2018","journal-title":"Mol Nutr Food Res"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13318-015-0315-0","article-title":"Effect of Lactobacillus casei on the pharmacokinetics of amiodarone in Male Wistar rats","volume":"42","author":"Matuskova","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.numecd.2025.104379_bib42","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.apsb.2021.01.009","article-title":"Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment","volume":"11","author":"Shang","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"1\u20132","key":"10.1016\/j.numecd.2025.104379_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2012.10.052","article-title":"Xenobiotics shape the physiology and gene expression of the active human gut microbiome","volume":"152","author":"Maurice","year":"2013","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1021\/acsinfecdis.7b00166","article-title":"Transformation of the anticancer drug doxorubicin in the Human Gut microbiome","volume":"4","author":"Yan","year":"2018","journal-title":"ACS Infect Dis"},{"issue":"6","key":"10.1016\/j.numecd.2025.104379_bib45","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4093\/dmj.2019.0147","article-title":"Role of intestinal microbiota in metabolism of voglibose in vitro and in vivo","volume":"44","author":"Nepal","year":"2020","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.numecd.2025.104379_bib46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jpba.2017.12.011","article-title":"Metabolic analysis of Panax notoginseng saponins with gut microbiota-mediated biotransformation by HPLC-DAD-Q-TOF-MS\/MS","volume":"150","author":"Chen","year":"2018","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"10.1016\/j.numecd.2025.104379_bib47","first-page":"231","article-title":"Quantification of Panax notoginseng saponins metabolites in rat plasma with in vivo gut microbiota-mediated biotransformation by HPLC-MS\/MS","volume":"17","author":"Guo","year":"2019","journal-title":"Chin J Nat Med"},{"issue":"3","key":"10.1016\/j.numecd.2025.104379_bib48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0022-3565(25)29238-2","article-title":"The role of intestinal bacteria in the metabolism of salicylazosulfapyridine","volume":"181","author":"Peppercorn","year":"1972","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"9","key":"10.1016\/j.numecd.2025.104379_bib49","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1124\/dmd.114.058354","article-title":"Gut microbiota-mediated drug interactions between lovastatin and antibiotics","volume":"42","author":"Yoo","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.numecd.2025.104379_bib50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamainternmed.2013.13957","article-title":"Warfarin interactions with antibiotics in the ambulatory care setting","volume":"174","author":"Clark","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.thromres.2009.11.032","article-title":"Small intestinal bacterial overgrowth and warfarin dose requirement variability","volume":"126","author":"Giuliano","year":"2010","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.numecd.2025.104379_bib52","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nrgastro.2017.20","article-title":"Gut microbiota modulation of chemotherapy efficacy and toxicity","volume":"14","author":"Alexander","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6264","key":"10.1016\/j.numecd.2025.104379_bib53","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.numecd.2025.104379_bib54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.numecd.2025.104379_bib55","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.4345","article-title":"Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug","volume":"23","author":"Wu","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.numecd.2025.104379_bib56","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.lfs.2019.04.009","article-title":"In vivo pharmacodynamic and pharmacokinetic effects of metformin mediated by the gut microbiota in rats","volume":"226","author":"Wu","year":"2019","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.numecd.2025.104379_bib57","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cmet.2020.07.012","article-title":"Microbial imidazole propionate affects responses to metformin through p38\u03b3-Dependent inhibitory AMPK phosphorylation","volume":"32","author":"Koh","year":"2020","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.numecd.2025.104379_bib58","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cmet.2020.06.011","article-title":"The gut microbiota in prediabetes and diabetes: a population-based cross-sectional Study","volume":"32","author":"Wu","year":"2020","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.numecd.2025.104379_bib59","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s13300-017-0226-y","article-title":"Effects of acarbose on the gut Microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial","volume":"8","author":"Zhang","year":"2017","journal-title":"Diabetes therapy : research, treatment and education of diabetes and related disorders"},{"issue":"7887","key":"10.1016\/j.numecd.2025.104379_bib60","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41586-021-04091-0","article-title":"The human microbiome encodes resistance to the antidiabetic drug acarbose","volume":"600","author":"Balaich","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.numecd.2025.104379_bib61","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1002\/jcb.26638","article-title":"Mechanistic and structural insight into promiscuity based metabolism of cardiac drug digoxin by gut microbial enzyme","volume":"119","author":"Kumar","year":"2018","journal-title":"J Cell Biochem"},{"issue":"2","key":"10.1016\/j.numecd.2025.104379_bib62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3988\/jcn.2016.12.2.147","article-title":"Association between Parkinson's Disease and Helicobacter Pylori","volume":"12","author":"\u00c7amc\u0131","year":"2016","journal-title":"J Clin Neurol"},{"issue":"25","key":"10.1016\/j.numecd.2025.104379_bib63","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.3748\/wjg.v22.i25.5742","article-title":"Gut dysfunction in Parkinson's disease","volume":"22","author":"Mukherjee","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1758834009355164","article-title":"Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management","volume":"2","author":"Stein","year":"2010","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.numecd.2025.104379_bib65","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00535-009-0102-2","article-title":"Present status and strategy of NSAIDs-induced small bowel injury","volume":"44","author":"Higuchi","year":"2009","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib66","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/hep.29327","article-title":"The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat","volume":"67","author":"Yip","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2025.104379_bib67","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fgene.2018.00212","article-title":"Microbiome research is becoming the key to better understanding health and nutrition","volume":"9","author":"Hadrich","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.numecd.2025.104379_bib68","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3389\/fmicb.2015.01050","article-title":"Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches","volume":"6","author":"Beliz\u00e1rio","year":"2015","journal-title":"Front Microbiol"},{"issue":"7753","key":"10.1016\/j.numecd.2025.104379_bib69","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-019-0965-1","article-title":"A new genomic blueprint of the human gut microbiota","volume":"568","author":"Almeida","year":"2019","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.numecd.2025.104379_bib70","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.01107-17","article-title":"Initial gut microbial composition as a key factor driving host response to antibiotic treatment, as exemplified by the presence or absence of commensal Escherichia coli","volume":"83","author":"Ju","year":"2017","journal-title":"Appl Environ Microbiol"},{"issue":"4","key":"10.1016\/j.numecd.2025.104379_bib71","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc21-2358","article-title":"Gut microbiome composition is predictive of incident type 2 diabetes in a population cohort of 5,572 Finnish adults","volume":"45","author":"Ruuskanen","year":"2022","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.numecd.2025.104379_bib72","article-title":"Human gut antibiotic resistome and progression of diabetes","volume":"9","author":"Shuai","year":"2022","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"10.1016\/j.numecd.2025.104379_bib73","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/gutjnl-2020-323617","article-title":"Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial","volume":"71","author":"Ng","year":"2022","journal-title":"Gut"},{"issue":"16","key":"10.1016\/j.numecd.2025.104379_bib74","article-title":"Decreased abundance of Akkermansia muciniphila leads to the impairment of insulin secretion and glucose homeostasis in lean type 2 diabetes","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"10.1016\/j.numecd.2025.104379_bib75","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2337\/dc19-2533","article-title":"Microbiota-Related metabolites and the risk of type 2 diabetes","volume":"43","author":"Vangipurapu","year":"2020","journal-title":"Diabetes Care"},{"issue":"7762","key":"10.1016\/j.numecd.2025.104379_bib76","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","article-title":"Mapping human microbiome drug metabolism by gut bacteria and their genes","volume":"570","author":"Zimmermann","year":"2019","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.numecd.2025.104379_bib77","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1210\/clinem\/dgac210","article-title":"Cardiovascular benefits of empagliflozin are associated with Gut Microbiota and plasma metabolites in type 2 diabetes","volume":"107","author":"Deng","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.numecd.2025.104379_bib78","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.3748\/wjg.v26.i23.3225","article-title":"Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice","volume":"26","author":"Herat","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.numecd.2025.104379_bib79","article-title":"Canagliflozin prevents lipid accumulation, mitochondrial dysfunction, and Gut microbiota dysbiosis in mice with diabetic cardiovascular disease","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.numecd.2025.104379_bib80","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3389\/fendo.2020.00635","article-title":"Dapagliflozin modulates the fecal microbiota in a type 2 diabetic rat model","volume":"11","author":"Yang","year":"2020","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib81","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12933-018-0708-x","article-title":"SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice","volume":"17","author":"Lee","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.numecd.2025.104379_bib82","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.diabet.2019.11.005","article-title":"Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: results of a double-blind randomized trial in patients with type 2 diabetes","volume":"46","author":"van Bommel","year":"2020","journal-title":"Diabetes Metab"},{"issue":"8","key":"10.1016\/j.numecd.2025.104379_bib83","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s00125-018-4647-6","article-title":"The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice","volume":"61","author":"Olivares","year":"2018","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.numecd.2025.104379_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184735","article-title":"Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats","volume":"12","author":"Zhang","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000717","article-title":"Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats","volume":"7","author":"Zhang","year":"2019","journal-title":"BMJ open diabetes research & care"},{"key":"10.1016\/j.numecd.2025.104379_bib86","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13098-015-0075-7","article-title":"Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice","volume":"7","author":"Stenman","year":"2015","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"10.1016\/j.numecd.2025.104379_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101223","article-title":"Liraglutide and sitagliptin have no effect on intestinal microbiota composition: a 12-week randomized placebo-controlled trial in adults with type 2 diabetes","volume":"47","author":"Smits","year":"2021","journal-title":"Diabetes Metab"},{"issue":"7","key":"10.1016\/j.numecd.2025.104379_bib88","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00592-020-01657-8","article-title":"Liraglutide targets the gut microbiota and the intestinal immune system to regulate insulin secretion","volume":"58","author":"Charpentier","year":"2021","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib89","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1535370217743765","article-title":"Featured article: structure moderation of gut microbiota in liraglutide-treated diabetic male rats","volume":"243","author":"Zhang","year":"2018","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.numecd.2025.104379_bib90","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.11128","article-title":"Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus","volume":"9","author":"Shang","year":"2021","journal-title":"PeerJ"},{"issue":"4","key":"10.1016\/j.numecd.2025.104379_bib91","doi-asserted-by":"crossref","first-page":"G367","DOI":"10.1152\/ajpgi.00232.2016","article-title":"Involvement of gut microbiota in association between GLP-1\/GLP-1 receptor expression and gastrointestinal motility","volume":"312","author":"Yang","year":"2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.9","article-title":"Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects","volume":"1","author":"Wang","year":"2018","journal-title":"Endocrinology, diabetes & metabolism"},{"issue":"5","key":"10.1016\/j.numecd.2025.104379_bib93","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/1753-0407.12232","article-title":"Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus","volume":"7","author":"Su","year":"2015","journal-title":"J Diabetes"},{"issue":"6","key":"10.1016\/j.numecd.2025.104379_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/nu13062107","article-title":"Habitual dietary intake affects the altered pattern of gut microbiome by acarbose in patients with type 2 diabetes","volume":"13","author":"Takewaki","year":"2021","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib95","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41467-017-01682-2","article-title":"Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment","volume":"8","author":"Gu","year":"2017","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.numecd.2025.104379_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/nu10030340","article-title":"ChREBP-Knockout mice show sucrose intolerance and fructose malabsorption","volume":"10","author":"Kato","year":"2018","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.numecd.2025.104379_bib97","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1507\/endocrj.EJ15-0747","article-title":"Beneficial effects of voglibose administration on body weight and lipid metabolism via gastrointestinal bile acid modification","volume":"63","author":"Do","year":"2016","journal-title":"Endocr J"},{"issue":"7","key":"10.1016\/j.numecd.2025.104379_bib98","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1248\/bpb.b17-00978","article-title":"Comparisons of effects on intestinal short-chain fatty acid concentration after exposure of two glycosidase inhibitors in mice","volume":"41","author":"Xu","year":"2018","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.numecd.2025.104379_bib99","article-title":"Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db\/db mice","volume":"133","author":"Madsen","year":"2021","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.numecd.2025.104379_bib100","article-title":"919 syrup inhibits ROS-mediated leptin-induced anorexia by activating PPAR\u03b3 and improves gut flora abnormalities","volume":"138","author":"Xing","year":"2021","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.numecd.2025.104379_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112465","article-title":"Metformin action over gut microbiota is related to weight and glycemic control in gestational diabetes mellitus: a randomized trial","volume":"145","author":"Molina-Vega","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.numecd.2025.104379_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108985","article-title":"Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acids","volume":"178","author":"Lee","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.numecd.2025.104379_bib103","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02392-17","article-title":"Structural alteration of Gut Microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula: a multicenter, randomized, open label clinical trial","volume":"9","author":"Tong","year":"2018","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib104","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41387-021-00169-w","article-title":"Metformin alleviates choline diet-induced TMAO elevation in C57BL\/6J mice by influencing gut-microbiota composition and functionality","volume":"11","author":"Su","year":"2021","journal-title":"Nutr Diabetes"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib105","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41467-022-28743-5","article-title":"Intestinal AMPK modulation of microbiota mediates crosstalk with brown fat to control thermogenesis","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.numecd.2025.104379_bib106","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/cts.13051","article-title":"Effects of vancomycin-induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects","volume":"14","author":"Kim","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.numecd.2025.104379_bib107","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jcjd.2021.08.001","article-title":"Metformin reduces blood glucose in treatment-naive type 2 diabetes by altering the gut microbiome","volume":"46","author":"He","year":"2022","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.numecd.2025.104379_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112448","article-title":"Gut microbiota of patients with type 2 diabetes and gastrointestinal intolerance to metformin differs in composition and functionality from tolerant patients","volume":"145","author":"D\u00edaz-Perdigones","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.numecd.2025.104379_bib109","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/gutjnl-2012-303839","article-title":"An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice","volume":"63","author":"Shin","year":"2014","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.numecd.2025.104379_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100778","article-title":"Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus","volume":"9","author":"Napolitano","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.numecd.2025.104379_bib111","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201700954","article-title":"Stachyose improves inflammation through Modulating Gut Microbiota of high-fat Diet\/Streptozotocin-Induced type 2 diabetes in rats","volume":"62","author":"Liu","year":"2018","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.numecd.2025.104379_bib112","article-title":"The F\/B ratio as a biomarker for inflammation in COVID-19 and T2D: impact of metformin","volume":"163","author":"Petakh","year":"2023","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"issue":"3","key":"10.1016\/j.numecd.2025.104379_bib113","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1007\/s12020-024-03828-x","article-title":"Metformin-induced changes of the gut microbiota in patients with type 2 diabetes mellitus: results from a prospective cohort study","volume":"85","author":"Gao","year":"2024","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib114","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56684-5","article-title":"Butyrate attenuated fat gain through gut microbiota modulation in db\/db mice following dapagliflozin treatment","volume":"9","author":"Oh","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2025.104379_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.1048693","article-title":"Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet","volume":"9","author":"Zhao","year":"2022","journal-title":"Front Nutr"},{"issue":"3","key":"10.1016\/j.numecd.2025.104379_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031105","article-title":"Gut Microbiota and short chain fatty acids: implications in glucose homeostasis","volume":"23","author":"Portincasa","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.numecd.2025.104379_bib117","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clnu.2022.10.024","article-title":"Butyrate's role in human health and the current progress towards its clinical application to treat gastrointestinal disease","volume":"42","author":"Hodgkinson","year":"2023","journal-title":"Clin Nutr"},{"issue":"8","key":"10.1016\/j.numecd.2025.104379_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087184","article-title":"The effects of cardioprotective antidiabetic therapy on microbiota in patients with type 2 diabetes Mellitus-A systematic review","volume":"24","author":"Bica","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"27","key":"10.1016\/j.numecd.2025.104379_bib119","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.2174\/1381612824666180912143434","article-title":"Effect of dapagliflozin on intestinal flora in MafA-deficient mice","volume":"24","author":"Li","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.numecd.2025.104379_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156979","article-title":"Integrated analysis of metabolomics, network pharmacology, and intestinal microbiota reveals Tibetan herb e'se ameliorate disorders of glycolipid metabolism in db\/db mice","volume":"145","author":"Zheng","year":"2025","journal-title":"Phytomedicine : international journal of phytotherapy and phytopharmacology"},{"issue":"6382","key":"10.1016\/j.numecd.2025.104379_bib121","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aar3318","article-title":"Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection","volume":"359","author":"Thaiss","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.numecd.2025.104379_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2021.101507","article-title":"Gut microbiome, prebiotics, intestinal permeability and diabetes complications","volume":"35","author":"Snelson","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.numecd.2025.104379_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1347047","article-title":"Understanding the action mechanisms of metformin in the gastrointestinal tract","volume":"15","author":"Cheng","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib124","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1530\/EC-20-0431","article-title":"New insights into the links between anti-diabetes drugs and gut microbiota","volume":"10","author":"Hu","year":"2021","journal-title":"Endocrine connections"},{"issue":"2","key":"10.1016\/j.numecd.2025.104379_bib125","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2274124","article-title":"Gut microbiota regulates postprandial GLP-1 response via ileal bile acid-TGR5 signaling","volume":"15","author":"Wang","year":"2023","journal-title":"Gut Microbes"},{"issue":"8","key":"10.1016\/j.numecd.2025.104379_bib126","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s42255-025-01336-4","article-title":"Combining a diet rich in fermentable carbohydrates with metformin improves glycaemic control and reshapes the gut microbiota in people with prediabetes","volume":"7","author":"Chu","year":"2025","journal-title":"Nat Metab"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib127","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/ajcn\/68.1.118","article-title":"Short-chain fatty acid-supplemented total parenteral nutrition alters intestinal structure, glucose transporter 2 (GLUT2) mRNA and protein, and proglucagon mRNA abundance in normal rats","volume":"68","author":"Tappenden","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.numecd.2025.104379_bib128","article-title":"Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus","volume":"14","author":"Wu","year":"2023","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.numecd.2025.104379_bib129","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2192155","article-title":"Glycoursodeoxycholic acid regulates bile acids level and alters gut microbiota and glycolipid metabolism to attenuate diabetes","volume":"15","author":"Chen","year":"2023","journal-title":"Gut Microbes"},{"issue":"2","key":"10.1016\/j.numecd.2025.104379_bib130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/dom.13869","article-title":"Mechanism of glucose-lowering by metformin in type 2 diabetes: role of bile acids","volume":"22","author":"Sansome","year":"2020","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2025.104379_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.956203","article-title":"The potential role of lactulose pharmacotherapy in the treatment and prevention of diabetes","volume":"13","author":"Chu","year":"2022","journal-title":"Front Endocrinol"},{"issue":"7581","key":"10.1016\/j.numecd.2025.104379_bib132","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature15766","article-title":"Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota","volume":"528","author":"Forslund","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.numecd.2025.104379_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1044030","article-title":"Gut microbiota is correlated with gastrointestinal adverse events of metformin in patients with type 2 diabetes","volume":"13","author":"Huang","year":"2022","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.numecd.2025.104379_bib134","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s00125-019-4848-7","article-title":"Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study","volume":"62","author":"Bryrup","year":"2019","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.numecd.2025.104379_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204317","article-title":"Association of metformin administration with gut microbiome dysbiosis in healthy volunteers","volume":"13","author":"Elbere","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.numecd.2025.104379_bib136","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1177\/1932296815577425","article-title":"Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels","volume":"9","author":"Burton","year":"2015","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.numecd.2025.104379_bib137","article-title":"Human Microbiota and breast Cancer-Is there any relevant Link?-A literature review and new Horizons toward","volume":"12","author":"Alpuim Costa","year":"2021","journal-title":"Personalised Medicine Frontiers in microbiology"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325005344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325005344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:22:33Z","timestamp":1769170953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475325005344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":137,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0939475325005344"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104379","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacomicrobiomics: Exploring the role of gut microbiota in type 2 diabetes and antidiabetic drug mechanisms","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104379"}}